ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1856

Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous SSc
Abstract Number: 1858

Serum Interferon Score Is a Biomarker of Active Disease in Patients with Early Diffuse Cutaneous Systemic Sclerosis Enrolled in the Prospective Registry of Early Systemic Sclerosis (PRESS) Cohort
Abstract Number: 1379

Serum Levels of the Soluble Receptor for Advanced Glycation Endproducts Are Prospectively Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
Abstract Number: 1206

Serum Levels of Total IgA Anti-cyclic Citrullinated Protein Antibodies Predict 11-year Radiographic Outcome in Early Rheumatoid Arthritis
Abstract Number: 1091

Serum Metabolomic Profiling Identifies Potential Biomarkers in Arthritis in the Elderly
Abstract Number: 0863

Serum Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and Cardiovascular Risk in Systemic Lupus Erythematosus: A Longitudinal Cohort Study
Abstract Number: 0662

Serum Urate Reduction Is Causally Associated with Flare Outcomes in People with Gout: Evidence for Surrogate Status from a Pooled Analysis of 2 Randomized Trials
Abstract Number: 1274

Severe Flares Are Associated with a Poorer Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients
Abstract Number: 1901

Severe Foot Symptoms Are Associated with Mortality: The Johnston County Osteoarthritis Project
Abstract Number: 1655

Severe Respiratory Infections in Rheumatoid Arthritis Patients with Biologic Therapy: Comparative Study Between Vaccinated and Non Vaccinated Patients
Abstract Number: 0393

Severity and Impact of Gastrointestinal Symptoms in Patients with SSc-ILD Treated with Nintedanib: Data from SENSCIS-ON
Abstract Number: 1534

Severity Factors of Covid-19 Infection in Rheumatic Immune-mediated Inflammatory Diseases: Study in a Single University Hospital
Abstract Number: 1847

Severity of Gastroesophageal Reflux, but Not the Use of Proton Pump Inhibitors, Is Associated with Radiographic Progression of Interstitial Lung Disease in Systemic Sclerosis
Abstract Number: 0614

Sex and Race Based Utilization of Healthcare for Ocular Inflammation and Infection: Comparing the Results from the Medicare and the IRIS Data
Abstract Number: 0597

Sex Differences in Multimorbidity Between Patients with Systemic Lupus Erythematosus and Comparators in a Large Nationwide US Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].